Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-10, Vol.27, p.vi209-vi209 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | vi209 |
|---|---|
| container_issue | |
| container_start_page | vi209 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Melero, I. Sangro, B. Yau, T. Hsu, C. Kudo, M. Crocenzi, T. Kim, T.-Y. Choo, S.-P. Trojan, J. Meyer, T. Welling, T.H. Yeo, W. Chopra, A. Anderson, J. De Cruz, C.l.a. Lang, L. Neely, J. El-Khoueiry, A. |
| description | |
| doi_str_mv | 10.1093/annonc/mdw371.07 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw371_07</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419442440</els_id><sourcerecordid>S0923753419442440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3217-dacc0876b25335c4dffa70259c5a36b0854bc0b02b2eac2f9bffe7d94fe682d13</originalsourceid><addsrcrecordid>eNp1kLtu3DAQRQkjAbxx0qeccreQlw89Vu4CIX4ANlwkqYUROYSYSJRActfQL-UrrcWmTTUDDM7ci8PYV8FvBa_VHr2fvN6P5k1V4pZXV2wjirLODjwXH9iG11JlVaHya_Ypxt-c87KW9Yb9_YGW0gLoDcyBBjc6j2EBstZp1AtMFrw7TcNxxA6253UHzsOMyZFPEbZzijt4c6kHNCf0mgz0tJ4nTcNwHDCAxqCdn0aELT42ze4Onnyi4MY1FYclunhOST3B3GMkEHsJTU_6zwsmynjOIaajWT6zjxaHSF_-zRv26_77z-Yxe359eGq-PWdaSVFlBrXmh6rsZKFUoXNjLVZcFrUuUJUdPxR5p3nHZScJtbR1Zy1Vps4tlQdphLph_PJXhynGQLad166rlFbw9uy6vbhuL65bXq3I3QWhtdfJUWijXvWsLlwgnVozuf_D77EEi9c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Melero, I. ; Sangro, B. ; Yau, T. ; Hsu, C. ; Kudo, M. ; Crocenzi, T. ; Kim, T.-Y. ; Choo, S.-P. ; Trojan, J. ; Meyer, T. ; Welling, T.H. ; Yeo, W. ; Chopra, A. ; Anderson, J. ; De Cruz, C.l.a. ; Lang, L. ; Neely, J. ; El-Khoueiry, A.</creator><creatorcontrib>Melero, I. ; Sangro, B. ; Yau, T. ; Hsu, C. ; Kudo, M. ; Crocenzi, T. ; Kim, T.-Y. ; Choo, S.-P. ; Trojan, J. ; Meyer, T. ; Welling, T.H. ; Yeo, W. ; Chopra, A. ; Anderson, J. ; De Cruz, C.l.a. ; Lang, L. ; Neely, J. ; El-Khoueiry, A.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdw371.07</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2016-10, Vol.27, p.vi209-vi209</ispartof><rights>2016 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3217-dacc0876b25335c4dffa70259c5a36b0854bc0b02b2eac2f9bffe7d94fe682d13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Melero, I.</creatorcontrib><creatorcontrib>Sangro, B.</creatorcontrib><creatorcontrib>Yau, T.</creatorcontrib><creatorcontrib>Hsu, C.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><creatorcontrib>Crocenzi, T.</creatorcontrib><creatorcontrib>Kim, T.-Y.</creatorcontrib><creatorcontrib>Choo, S.-P.</creatorcontrib><creatorcontrib>Trojan, J.</creatorcontrib><creatorcontrib>Meyer, T.</creatorcontrib><creatorcontrib>Welling, T.H.</creatorcontrib><creatorcontrib>Yeo, W.</creatorcontrib><creatorcontrib>Chopra, A.</creatorcontrib><creatorcontrib>Anderson, J.</creatorcontrib><creatorcontrib>De Cruz, C.l.a.</creatorcontrib><creatorcontrib>Lang, L.</creatorcontrib><creatorcontrib>Neely, J.</creatorcontrib><creatorcontrib>El-Khoueiry, A.</creatorcontrib><title>Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kLtu3DAQRQkjAbxx0qeccreQlw89Vu4CIX4ANlwkqYUROYSYSJRActfQL-UrrcWmTTUDDM7ci8PYV8FvBa_VHr2fvN6P5k1V4pZXV2wjirLODjwXH9iG11JlVaHya_Ypxt-c87KW9Yb9_YGW0gLoDcyBBjc6j2EBstZp1AtMFrw7TcNxxA6253UHzsOMyZFPEbZzijt4c6kHNCf0mgz0tJ4nTcNwHDCAxqCdn0aELT42ze4Onnyi4MY1FYclunhOST3B3GMkEHsJTU_6zwsmynjOIaajWT6zjxaHSF_-zRv26_77z-Yxe359eGq-PWdaSVFlBrXmh6rsZKFUoXNjLVZcFrUuUJUdPxR5p3nHZScJtbR1Zy1Vps4tlQdphLph_PJXhynGQLad166rlFbw9uy6vbhuL65bXq3I3QWhtdfJUWijXvWsLlwgnVozuf_D77EEi9c</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Melero, I.</creator><creator>Sangro, B.</creator><creator>Yau, T.</creator><creator>Hsu, C.</creator><creator>Kudo, M.</creator><creator>Crocenzi, T.</creator><creator>Kim, T.-Y.</creator><creator>Choo, S.-P.</creator><creator>Trojan, J.</creator><creator>Meyer, T.</creator><creator>Welling, T.H.</creator><creator>Yeo, W.</creator><creator>Chopra, A.</creator><creator>Anderson, J.</creator><creator>De Cruz, C.l.a.</creator><creator>Lang, L.</creator><creator>Neely, J.</creator><creator>El-Khoueiry, A.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161001</creationdate><title>Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study</title><author>Melero, I. ; Sangro, B. ; Yau, T. ; Hsu, C. ; Kudo, M. ; Crocenzi, T. ; Kim, T.-Y. ; Choo, S.-P. ; Trojan, J. ; Meyer, T. ; Welling, T.H. ; Yeo, W. ; Chopra, A. ; Anderson, J. ; De Cruz, C.l.a. ; Lang, L. ; Neely, J. ; El-Khoueiry, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3217-dacc0876b25335c4dffa70259c5a36b0854bc0b02b2eac2f9bffe7d94fe682d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melero, I.</creatorcontrib><creatorcontrib>Sangro, B.</creatorcontrib><creatorcontrib>Yau, T.</creatorcontrib><creatorcontrib>Hsu, C.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><creatorcontrib>Crocenzi, T.</creatorcontrib><creatorcontrib>Kim, T.-Y.</creatorcontrib><creatorcontrib>Choo, S.-P.</creatorcontrib><creatorcontrib>Trojan, J.</creatorcontrib><creatorcontrib>Meyer, T.</creatorcontrib><creatorcontrib>Welling, T.H.</creatorcontrib><creatorcontrib>Yeo, W.</creatorcontrib><creatorcontrib>Chopra, A.</creatorcontrib><creatorcontrib>Anderson, J.</creatorcontrib><creatorcontrib>De Cruz, C.l.a.</creatorcontrib><creatorcontrib>Lang, L.</creatorcontrib><creatorcontrib>Neely, J.</creatorcontrib><creatorcontrib>El-Khoueiry, A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melero, I.</au><au>Sangro, B.</au><au>Yau, T.</au><au>Hsu, C.</au><au>Kudo, M.</au><au>Crocenzi, T.</au><au>Kim, T.-Y.</au><au>Choo, S.-P.</au><au>Trojan, J.</au><au>Meyer, T.</au><au>Welling, T.H.</au><au>Yeo, W.</au><au>Chopra, A.</au><au>Anderson, J.</au><au>De Cruz, C.l.a.</au><au>Lang, L.</au><au>Neely, J.</au><au>El-Khoueiry, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study</atitle><jtitle>Annals of oncology</jtitle><date>2016-10-01</date><risdate>2016</risdate><volume>27</volume><spage>vi209</spage><epage>vi209</epage><pages>vi209-vi209</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdw371.07</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-10, Vol.27, p.vi209-vi209 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw371_07 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A08%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20preliminary%20efficacy%20of%20nivolumab%20(nivo)%20in%20patients%20(pts)%20with%20advanced%20hepatocellular%20carcinoma%20(aHCC):%20Interim%20analysis%20of%20the%20phase%201/2%20CheckMate-040%20study&rft.jtitle=Annals%20of%20oncology&rft.au=Melero,%20I.&rft.date=2016-10-01&rft.volume=27&rft.spage=vi209&rft.epage=vi209&rft.pages=vi209-vi209&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdw371.07&rft_dat=%3Celsevier_cross%3ES0923753419442440%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753419442440&rfr_iscdi=true |